Skip to main
GH
GH logo

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health has reported a two-year revenue compound annual growth rate (CAGR) increase of 28% for the period from 2023 to 2025, driven by anticipated strength in colorectal cancer (CRC), breast cancer, and other indicators, along with new monitoring applications and product upgrades. The company has exceeded revenue estimates from its new test, Shield, and raised its annual revenue guidance for the test, anticipating approximately 31% year-over-year growth for 2025. Furthermore, the introduction of Reveal as the fastest-growing oncology test and improvements in reimbursement coverage for breast cancer testing are expected to enhance average selling prices (ASPs) and bolster overall volumes, positioning Guardant Health favorably within the market.

Bears say

Guardant Health's medium-term revenue guidance for its Shield product was perceived as underwhelming, contributing to concerns about future earnings potential. The company's adjusted EBITDA loss of $45.5 million in the third quarter of 2025 raises questions about its financial health and sustainability, particularly in the context of ongoing high research and development expenditures. Additionally, uncertainties surrounding regulatory approvals, reimbursement processes, and potential delays in product launches could further destabilize the company's stock performance.

GH has been analyzed by 21 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 21 analysts, GH has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $79.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $79.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.